Overview
A biobank has been created to investigate the prognostic value of biomarkers (mainly BNP) in patients implanted with durable mechanical assist devices comparing patients with advanced HF supported by MCS with those who are transplanted and those who remain on optimal medical therapy.
Patients will be followed up for 25 years after inclusion.
Description
All patients referred for advanced HF treatment at the Dept of Cardiology at Rigshospitalet.
Eligibility
Inclusion Criteria:
- All patients referred for evaluation for advanced HF treatment at the Rigshospital in Denmark
- Age>18 years
Exclusion Criteria:
- No consent